HUH1_LIVER
HCC · Hepatocellular Carcinoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- HCC
- cancer_type_detailed
- Hepatocellular Carcinoma
- subtype
- —
- cancer_type
- HCC
- ccle_sample_id
- HUH1_LIVER
- synthetic_from_ccle
- true
- display_name
- huH-1
- ccle_lineage
- liver
- ccle_lineage_subtype
- hepatocellular_carcinoma
- ccle_lineage_sub_subtype
- hbs_antigen_carrier
- oncotree_code
- HCC
- cancer_type_detailed
- Hepatocellular Carcinoma
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- XENOBIOTIC_METABOLISM+1.113
- COAGULATION+0.965
- BILE_ACID_METABOLISM+0.913
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.552
- ANGIOGENESIS+0.551
- APICAL_SURFACE+0.538
- MYC_TARGETS_V2+0.534
- FATTY_ACID_METABOLISM+0.456
- ADIPOGENESIS+0.301
- OXIDATIVE_PHOSPHORYLATION+0.263
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.419
- E2F_TARGETS-0.365
- UV_RESPONSE_DN-0.347
- G2M_CHECKPOINT-0.323
- MITOTIC_SPINDLE-0.286
- APICAL_JUNCTION-0.230
- INTERFERON_GAMMA_RESPONSE-0.222
- INTERFERON_ALPHA_RESPONSE-0.222
- PI3K_AKT_MTOR_SIGNALING-0.219
- HEDGEHOG_SIGNALING-0.209
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | JHH5_LIVER | HCC | — | 0.862 |
| 2 | HEPG2_LIVER | HCC | — | 0.824 |
| 3 | SRR9879284 | — | cohortA1 | 0.751 |
| 4 | HUH7_LIVER | HCC | — | 0.712 |
| 5 | HEP3B217_LIVER | HCC | — | 0.695 |
| 6 | AUR-AE6X-TTM1-A-1-1-R-A742-41 | — | E | 0.691 |
| 7 | AUR-AERY-TTM1-A-1-1-R-A742-41 | — | C | 0.685 |
| 8 | AUR-AD9I-TTM3-A-1-1-R-A542-39 | — | C | 0.675 |
| 9 | SNU878_LIVER | HCC | — | 0.672 |
| 10 | SRR5088842 | — | — | 0.666 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| XENOBIOTIC_METABOLISM | 1.113 | Inavolisib | — uncovered |
| COAGULATION | 0.965 | Binimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.913 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.552 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.551 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.538 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.534 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.456 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.301 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.263 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.233 | Inavolisib | — uncovered |
| PEROXISOME | 0.223 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.206 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.191 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.108 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.107 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.099 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.081 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.068 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.061 | Inavolisib | — uncovered |